• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Bard, Medtronic win Medicare reimbursement add-on for DCBs

Bard, Medtronic win Medicare reimbursement add-on for DCBs

August 3, 2015 By Fink Densford

Medtronic, Bard win Medicare add-on coverage for DCBMedtronic (NYSE:MDT) and C.R. Bard (NYSE:BCR) said today that angioplasty treatments with  drug-coated balloons will now be eligible for new technology add-on payments through the Centers for Medicare and Medicaid Services under Medicare’s hospital impatient prospective payment systems.

The add-on payment, with a maximum of $1,036, will help cover additional costs for treating patients for peripheral artery disease with Bard’s Lutonix and Medtronic’s In.Pact Admiral drug-coated balloon during inpatient settings.  The new coverage is slated to go into effect October 1.

“Medtronic has been leading the efforts with CMS to enhance access to DCB technology for the Medicare population, based on the substantially improved clinical outcomes in patients with PAD in the superficial femoral artery treated with theIn.Pact Admiral DCB technology, including significantly fewer repeat interventions and improved quality of life for these patients. Today’s decision will ultimately help to improve patient access to the In.Pact Admiral DCB, which provides significant improvement to the standard of care,” veep of Medtronic’s peripheral vascular business Brian Verrier said in a press release.

Medtronic said the In.Pact DCB won approval for transitional pass-through payment from CMS under the Medicare hospital outpatient prospective payment system in February this year.

“After providing reimbursement in the outpatient setting earlier this year, CMS has now provided additional reimbursement for the Lutonix DCB in the inpatient setting, which demonstrates the benefit to patients from this breakthrough technology,” CEO Timothy Ring said in a prepared statement.

The Lutonix was the first DCB approved by the FDA, C.R. Bard said.

C.R. Bard posted a classic beat-&-raise 2nd quarter last week, topping both sales and earnings expectations and raising its outlook for the rest of the year.

Filed Under: Catheters, Drug-Device Combinations, Food & Drug Administration (FDA), Medicare, Vascular Tagged With: C.R. Bard, Centers for Medicare and Medicaid Services (CMS)

More recent news

  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set
  • Apreo Health emerges from stealth with positive data for lung scaffold
  • Tivic adds new vagus nerve stim patent
  • Study backs Teleflex stapler for reducing post-op GERD rates

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy